Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Perspective Therapeutics filings document a clinical-stage radiopharmaceutical oncology business built around Lead-212 targeted therapy, imaging diagnostics, and regional manufacturing capabilities. Form 8-K reports include clinical-program exhibits, corporate presentations, preliminary financial information, and annual results for its VMT-α-NET, VMT01, and PSV359 programs.
The company’s SEC record also covers capital-structure matters, including common stock and pre-funded warrant offerings under a shelf registration statement, as well as material agreements, proxy disclosures on board matters, executive compensation, equity awards, shareholder voting items, governance, and other public-company reporting obligations.
Perspective Therapeutics, Inc. completed an underwritten equity offering, selling 39,576,088 shares of common stock and issuing pre-funded warrants to purchase 6,598,046 shares, raising approximately $175 million in gross proceeds.
The shares were priced at $3.79 each, and the pre-funded warrants at $3.789 each, reflecting a $0.001 exercise price. The company plans to use net proceeds to advance clinical development of its product candidates, invest in manufacturing facilities, and for working capital and other general corporate purposes, with potential additional use for future acquisitions or licensing opportunities.
Perspective Therapeutics, Inc. is conducting a primary offering of 39,576,088 shares of common stock and pre-funded warrants to purchase 6,598,046 shares of common stock. The shares are priced at $3.79 and the pre-funded warrants at $3.789, with a $0.001 exercise price per warrant share.
The company expects gross proceeds of $174,993,369.81 and net proceeds of approximately $164.0 million after underwriting discounts and expenses. Management plans to use the cash to advance clinical development of its radiopharmaceutical product candidates, invest in manufacturing facilities, and for working capital and general corporate purposes, with potential business development uses.
As of December 31, 2025, Perspective Therapeutics estimates it had approximately $144 million in cash, cash equivalents and short-term investments, and about 74.3 million shares outstanding. The company believes existing cash plus this raise should fund planned milestones and operations into late 2027, though investors will face immediate dilution given the offering price exceeds prior net tangible book value per share.
Perspective Therapeutics, Inc. filed an 8-K to note that it has updated its corporate presentation and posted it on its website. The presentation includes preliminary estimated and projected financial information, including estimated cash, cash equivalents and short-term investments as of December 31, 2025.
The company emphasizes that these figures are unaudited and have not been reviewed or compiled by its independent registered public accounting firm, WithumSmith+Brown, PC, which provides no assurance on the data. Actual results for the year ended December 31, 2025 may differ once closing procedures and final adjustments are completed.
Perspective Therapeutics, Inc. filed a current report to note that it updated its corporate presentation on January 14, 2026. The company is a Delaware corporation whose common stock trades on the NYSE American under the symbol CATX.
The updated corporate presentation is included as Exhibit 99.1 and is incorporated by reference into the Item 8.01 Other Events section. No new financial statements or major transactions are described in this excerpt, which focuses on making the refreshed investor materials publicly available.
Perspective Therapeutics, Inc. filed a current report to let investors know it has issued a new press release describing business updates and strategic priorities. The company states that the press release, dated January 12, 2026, is attached as an exhibit and incorporated by reference, meaning the detailed operational and strategic information is contained in that accompanying document rather than in the body of this report.
Perspective Therapeutics, Inc. reported that it issued a press release on January 9, 2026 sharing updated interim data from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET. This study involves patients with unresectable or metastatic neuroendocrine tumors that express somatostatin receptor subtype 2, a specific tumor marker. The updated data are being presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, held January 8–10, 2026 in San Francisco. Detailed clinical results are contained in the related press release, which is attached as an exhibit.
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G reporting beneficial ownership of 312,164 shares of Perspective Therapeutics Inc. common stock, representing 0.4% of the outstanding class. FMR LLC has sole voting power over 303,643 shares and sole dispositive power over 312,164 shares, while Johnson is reported with sole dispositive power over the same 312,164 shares.
The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Perspective Therapeutics. It also notes that one or more other persons may have rights to dividends or sale proceeds from these shares, but no other individual interest exceeds five percent of the company’s common stock.
Perspective Therapeutics, Inc. reported that it updated its corporate presentation on December 1, 2025. The new version is being made available to the market as an exhibit to a current report, giving investors and other stakeholders refreshed information about the company’s business and strategy. The company’s common stock continues to trade on the NYSE American under the symbol CATX.
Perspective Therapeutics, Inc. (CATX) reported an insider stock purchase by its Chief Accounting Officer on a Form 4. On 11/13/2025, the officer acquired 11,000 shares of common stock in an open market transaction coded “P” for purchase. The weighted average price paid was $2.0268 per share, with individual trades executed in a range from $2.0235 to $2.0300. Following this transaction, the officer beneficially owns 59,800 shares of Perspective Therapeutics common stock held directly.
Perspective Therapeutics (CATX) director Robert F. Williamson, III reported a Form 4 purchase of common stock. On 11/12/2025, he bought 9,498 shares (transaction code P) at $2.10 per share.
Following the transaction, the filing shows 9,864 shares held indirectly via the RFW3 Revocable Trust and 108,982 shares held directly. This reflects insider open-market buying and updates his reported holdings.